PROTAGONIST THERAPEUTICS,INC. (NASDAQ:PTGX) Files An 8-K Financial Statements and ExhibitsItem 9.01 Financial Statement and Exhibit
(d)Exhibits
|
Exhibit |
Description |
|
10.1† |
Exclusive License and Collaboration Agreement, by and between the Company and Janssen Biotech,Inc., dated May26, 2017. |
Exclusive License and Collaboration Agreement, by and between the Company and Janssen Biotech,Inc., dated May26, 2017.
† Confidential portions of this exhibit have been redacted and filed separately with the Securities and Exchange Commission Protagonist Therapeutics, Inc ExhibitEX-10.1 2 a17-18281_1ex10d1.htm EX-10.1 Exhibit 10.1 [ * ] = Certain confidential information contained in this document,…To view the full exhibit click here
About PROTAGONIST THERAPEUTICS,INC. (NASDAQ:PTGX)
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs. PTG-100 is an oral, alpha-4-beta-7 (a4b7) integrin-specific antagonist peptide product candidate, which has completed a Phase I clinical trial in normal healthy volunteers (NHVs). PTG-100 is being developed for treatment of moderate-to-severe ulcerative colitis (UC). PTG-200 is an oral Interleukin-23 receptor (IL-23R) antagonist being developed for moderate-to-severe Crohn’s disease (CD). PTG-200 is in investigational new drug (IND) enabling studies. PTG-300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases.
